Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention (RECOVERII)
Effect of Low-dose Intracoronary Reteplase During Primary Percutaneous Coronary Intervention on Myocardial Infarct Size in Patients With Acute Myocardial Infarction
Sponsor: Ge Junbo
Terminated
The study enrollment is slow due to the pandemic.
This PHASE3 trial investigates Acute ST-segment Elevation Myocardial Infarction and is currently terminated or withdrawn. Ge Junbo leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Mar 2023 — Oct 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE3
▶ Show 5 earlier versions
-
Sep 2021 — Sep 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ge Junbo
For direct contact, visit the study record on ClinicalTrials.gov .